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Available online 15 September 2016Sepsis is the dysregulated host response to an infection which leads to life-threatening organ dysfunction that
varies by host genomic factors. We conducted a genome-wide association study (GWAS) in 740 adult septic pa-
tients and focused on 28 day mortality as outcome. Variants with suggestive evidence for an association
(p ≤ 10−5) were validated in two additional GWA studies (n= 3470) and gene coding regions related to the var-
iants were assessed in an independent exome sequencing study (n = 74).
In the discovery GWAS, we identiﬁed 243 autosomal variants which clustered in 14 loci (p ≤ 10−5). The best as-
sociation signal (rs117983287; p = 8.16 × 10−8) was observed for a missense variant located at chromosome
9q21.2 in the VPS13A gene. VPS13A was further supported by additional GWAS (p = 0.03) and sequencing
data (p = 0.04). Furthermore, CRISPLD2 (p = 5.99 × 10−6) and a region on chromosome 13q21.33 (p =
3.34 × 10−7) were supported by both our data and external biological evidence.
We found 14 loci with suggestive evidence for an association with 28 day mortality and found supportive, con-
verging evidence for three of them in independent data sets. Elucidating the underlying biologicalmechanisms of
VPS13A, CRISPLD2, and the chromosome 13 locus should be a focus of future research activities.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Sepsis
Host response
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Sepsis is the dysregulated host response to an infection which leads
to life-threatening organ dysfunction according to the new Sepsis-3 def-
inition (Singer et al., 2016; Seymour et al., 2016). It can result in 28 day
mortalities of up to 60% (Engel et al., 2007; Angus andWax, 2001). Con-
sequently, there is an urgent need for new therapies but results from re-
cent large scale phase III randomized controlled intervention trials (e.gthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
240 A. Scherag et al. / EBioMedicine 12 (2016) 239–246Food and Drug Administration, 2011) have been disappointing. It has
been proposed to go “back to the drawing board” (Angus, 2011) taking
a fresh look at the biology that drives the sepsis processes (Cohen et al.,
2015).
As part of this discussion, there is new interest in host genomic fac-
tors that are rooted in the landmark publication by Sørensen et al.
(1988). These authors reported that if one biological parent died of an
infection, the risk to die of an infection in the offspring was strongly in-
creased (relative risk 4.52). This work stimulated the conduct of many
candidate gene association studies for sepsis susceptibility with incon-
sistent and essentially weak results (e.g. reviewed in Clark and
Baudouin, 2006). Moreover, focusing on sepsis susceptibility might be
too challenging given that recent evidence strongly supported a stron-
ger impact of the host genome to account for the variability during the
clinical disease course after sepsis onset (Petersen et al., 2010). Thus,
this and an accompanying report by Taudien et al. 2016 focus on host
genomic factors related to differential clinical disease course after sepsis
onset applying the new Sepsis-3 deﬁnition. While Taudien et al. 2016
report on deleterious single nucleotide variants and pathways, we de-
scribe a genome-wide association (GWA) study (GWAS) which by de-
sign is limited to common variants.
Of the two GWA studies related to sepsis reported so far (Man et al.,
2013; Rautanen et al., 2015) the former focused on treatment response
in 1446 patients with (severe) sepsis while the latter was aiming on
28 day mortality in 1533 patients with sepsis due to pneumonia. Both
GWAS used the consensus deﬁnition of sepsis from 2001 which did
not require the presence of an organ dysfunction (Levy et al., 2003)
and only Rautanen et al. (2015) consider host genomic factors related
to differential clinical disease course after sepsis onset. As their main
ﬁnding, Rautanen et al. (2015) report that a common genetic variation
in the FER (FER tyrosine kinase) gene is associated with a reduced
28 day mortality from sepsis due to pneumonia. They estimate an age-
adjusted odds ratio (OR) of 0.56 (95% conﬁdence interval (CI) [0.45–
0.69]; p = 5.6 × 10−8) for each C allele at rs4957796 in a joint analysis
of discovery and replication samples (total 2078 patients).
Here we report results derived under a similar study design focusing
on 28 day mortality in a discovery GWAS of 740 septic patients. We
follow-up our best GWAS loci with single nucleotide polymorphism
(SNP) allelic association signals below the signiﬁcance level
(p b 10−5), i.e. suggestive evidence for an association, in the discovery
meta-analysis by Rautanen et al. (2015) with 2534 patients with sepsis
due to pneumonia or abdominal infections combined and in another in-
dependent GWAS of the PROGRESS consortium with 936 patients with
conﬁrmed community acquired pneumonia (CAP) – both with mortali-
ty outcome data. Next, we elucidate the potential differential organ im-
pact of these variants by analyzing organ dysfunction scores after sepsis
onset. Finally, we follow-up the loci with the most signiﬁcant results
previously identiﬁed by Rautanen et al. (2015) and all 21 candidate
genes at or around our best GWAS loci in an independent exome se-
quencing study (Taudien et al. 2016 that included 74 patients with
treated sepsis and 28 day mortality outcome data.
2. Material & Methods
2.1. Study Design and Patients
2.1.1. Discovery GWAS
Our discovery GWAS included patients that participated in two ran-
domized controlled trials (RCTs) VISEP and MAXSEP of the SepNet
Study group (Brunkhorst et al., 2008; Brunkhorst et al., 2012). Both
RCTs ascertained patients of European ancestry who were admitted to
German intensive care units (ICUs) with a diagnosis of sepsis (see Ap-
pendix for deﬁnitions). For VISEP, patientswere recruited at 18 academ-
ic tertiary hospitals in Germany between 04/2003 and 06/2005 (n =
537). For MAXSEP, patients were recruited at 44 ICUs in Germany be-
tween 10/2007 and 03/2010 (n = 600). Here we analyzed a subgroupof patients from the two RCTs who gave additional written consent to
participate in a genetic study and who met patient-wise quality control
criteria (nVISEP = 410; nMAXSEP = 330). We included all 740 patients ir-
respective of treatment group but performed sensitivity analyses to ad-
dress potential effects of study arm. Supplementary Fig. 16 shows the
amount of organ dysfunction among (28 day) survivors and non-
survivors based on SOFA (sub-)scores.
2.1.2. Validation GWA Studies
(1)We contacted Rautanen et al. (2015) who looked-up our best 14
GWAS hits in their meta-analysis of three discovery GWAS cohorts
(GenOSept/GAinS; VASST; PROWESS) that included up to 2534 patients
with sepsis and information on the 28 day mortality outcome. For de-
tails on the cohort descriptions and the quality control we refer to the
original report (Rautanen et al., 2015). (2) In addition, we looked-up
our best 14 GWAS hits in a GWAS of patients from the PROGRESS
study. PROGRESS is a prospective multi-centric longitudinal observa-
tional study on patients hospitalized due to conﬁrmed CAP. Patients
were investigated for ﬁve consecutive days after enrolment including
comprehensive clinical and laboratory assessments. Vital status was
assessed at days 28, 180, and 360 after enrolment. PROGRESS is regis-
tered at ClinicalTrials.gov (registration number: NCT02782013).
2.1.3. Exome Sequencing Study
To further follow-up our ﬁndings, we performed a moderate-size
whole-exome sequencing study in an independent cohort of 74 patients
with treated sepsis again with European background which were re-
cruited at two University hospitals (n = 15 at the Jena University Hos-
pital, Germany and n = 59 at the University Hospital Athens, Greece).
Sepsis patients for this study were selected for extremely different clin-
ical disease courses - patients with co-morbidities who survived despite
an inappropriate empirically administered antimicrobial treatment
until the antibiogram became known (n = 37) vs. younger patients
with a lack of comorbidities who had a bad disease course (as docu-
mented by SOFA trajectories) or died early in the presence of appropri-
ate initial treatment (n= 37). A detailed characterization of all patients
is provided in Taudien et al. 2016.
Ethics approval was granted for the individual centers and the study
was conducted according to the ethical standards laid down in the Dec-
laration of Helsinki. Written, informed consent was obtained from all
patients or from a legal representative in case of critical illness. Table 1
shows patient characteristics of the analyzed patients in the discovery
GWAS, the validation GWAS (PROGRESS) and the exome sequencing
studies. Details on the validation GWA studies (GenOSept/GAinS;
VASST; PROWESS) are provided in Rautanen et al. (2015).
2.2. Procedures
2.2.1. Discovery GWAS
For the GWAS data (HumanOmniExpressExome arrays) we applied
stringent measures of quality control (QC) to remove unreliably geno-
typed patients or SNPs, population outliers as determined by
performing a principal component analysis of the genome-wide data,
and samples for which therewere sex discrepancies (details see Appen-
dix). The number of autosomal SNPs remaining for imputation were
644,699 which were subsequently imputed using IMPUTE2 (version
2.3.0) andwith 1000 Genomes Project data (phase 1, version 3) as a ref-
erence panel. After additional QC of the imputed data, 7,993,459 SNPs
were ﬁnally available for the genome-wide analysis (details see
Appendix).
2.2.2. Validation GWA Studies
(1) Genotyping of the patients in GenOSept/GAinS was performed
on Affymetrix 5.0 SNP arrays and Illumina Human
OmniExpressBeadChip SNP arrays. VASST and PROWESS were both ge-
notyped by Illumina Human 1 M-Duo BeadChip SNP array. All datasets
Table 1
Characteristics of the patients with treated severe sepsis/septic shock in the discovery GWAS, the independent (unpublished) validation GWAS in the PROGRESS study and the exome
sequencing study (Taudien et al., in press). For the cohort descriptions of the other validation GWA studies, we refer to the original report by Rautanen et al. (2015).
Discovery GWAS (n = 740) Validation GWAS PROGRESS (n = 936) Exome sequencing study (n = 74)
Deaths (or qualiﬁed intensive carea) within 28 days (%) 149 (20) 95 (10)a 12 (15)
Females (%) 284 (38) 399 (43) 23 (32)
Median age (Q1; Q3)b 67.0 (56.0; 75.0) 61.0 (44.0; 73.0) 59.0 (47.0; 77.8)
Patients with pneumonia (%) 298 (40) 936 (100) 9 (12)
Median APACHE II scorec (Q1; Q3)b 20.0 (16.0; 24.0) – 18.0 (14.0; 23.8)
Median SOFA scored (Q1;Q3)b 6.79 (4.94; 9.50)e 3.0 (2.0; 4.0)f 7.5 (5.0; 10.0)g
With microbiology (%) 603 (81) 612 (65) 74 (100)
Any pathogen identiﬁed (%) 534 (89)h 208 (34)h 69 (93)h
Gram-positive or gram-negative bacterial infection (%) 496 (82)h 177 (30)h 60 (81)h
Gram-positive infection only (%) 358 (59)h – 8 (11)h
Gram-negative infection only (%) 324 (54)h – 52 (70)h
Fungal infection (%) 172 (29)h 62 (10)h 2 (3)h
a In PROGRESS the outcome is deﬁned as death within 28 days or qualiﬁed intensive-care requiring ventilation, treatment with catecholamines, oxygenation or dialysis.
b First and third quartile.
c Acute Physiology and Chronic Health Evaluation II score.
d Sequential Organ Failure Assessment score, in the discovery GWAS.
e 14 day mean SOFA data from 714 of 740 patients.
f Worst SOFA score within 5 days.
g SOFA score at baseline.
h Percentages relative to the 603 or 612 patients with microbiology.
241A. Scherag et al. / EBioMedicine 12 (2016) 239–246were also imputed separately with IMPUTE2 and with 1000 Genomes
Project data as a reference panel. For details see Rautanen et al.
(2015). (2) Genotyping of the patients in PROGRESS was performed
using the Affymetrix Axiom-CAP2 microarray. The CAP2 array is a
genome-wide custom microarray. It contains Axiom-CEU content as
backbone but is enriched with candidate SNPs and regions. Genotype
calling was performed with Affymetrix power tools (version 1.15.1).
Sample ﬁlters comprise dish-qc b0.82, call-rate b 97%, implausible
dish-qc vs. call-rate, implausible relatedness, sex-mismatches and eth-
nic outliers identiﬁed by the 6SD outlier criterion of SMARTPCA. SNP ﬁl-
tering comprise the cluster plot quality metrices proposed by
Affymetrix (HetSO, HomRO, FLD), call-rate ≤ 97%, p-value of exact test
for Hardy-Weinberg equilibrium ≤ 10−6, p-value of plate
association ≤ 10−7, exclusion of monomorphic SNPs and non-
autosomal SNPs. A total of 589,205 SNPs fulﬁlled these criteria and
were used for imputation with the reference panel 1000 Genomes Pro-
ject data (phase 1, version 3). SHAPEIT v2.r790 was used for pre-
phasing and IMPUTE2 v2.3.1 was used for ﬁnal imputation.
2.2.3. Exome Sequencing Study
For the exome sequencing study, 2–3 μg DNA per sample was
fragmented on a Covaris M220 focused ultra-sonicator. Exomes were
enriched using Agilent SureSelect XT Human All Exon V5 + UTRs kits
targeting 74,856,280 bp in the coding sequence and untranslated re-
gions of 20,791 genes. The mean depth of sequence coverage was 91-
fold (range: 52- to 159-fold). Relative to the human reference genome
(GRCh37/hg19) we called 313,279 single nucleotide variants using the
Genome Analysis Toolkit (GATK 2.5) (DePristo et al., 2011) and we
again refer to Taudien et al. 2016 for details.
2.3. Statistical Analyses
2.3.1. Discovery GWAS
We analyzed all autosomal GWAS variants for the dichotomous out-
come 28 day mortality by logistic regression (log-additive genetic
model as implemented in SNPTEST, version 2.5) with age (linear), sex,
and the ﬁrst three principal components as covariates (model 1). Age
and sex are known to be strong determinants of mortality in patients
with sepsis (Martin et al., 2003) and principal components were used
to avoid confounding due to population structure. In addition, we
added APACHE II scores (linear) as covariates as a summary measure
of baselinemorbidity (model 2). Finally, we performed sensitivity anal-
yses by also including indicator variables for the treatment arm of theVISEP/MAXSEP trials for selected variants (p ≤ 10−5 in the primary
GWAS analysis). Association signals at SNP variants were summarized
as GWAS loci if more than one SNP signal had a p-value ≤10−5 within
a region of ±500 kb around the lead SNP. Details on the analysis of
the X-chromosome and the corresponding results, which were not the
focus of this report, are provided in the Appendix.
In the Appendix, we also provide details on the comparison-wise
statistical power of our discovery GWASwith n=740 patients to detect
an association with the dichotomous 28 day mortality outcome after
treated sepsis. Overall, ourGWAShad a power N 80% todetect strong ge-
netic effects on the 28 day mortality outcome.
2.3.2. Validation GWA Studies
(1) In short, the statistical analyses in the GWA studies (GenOSept/
GAinS; VASST; PROWESS) were similar to those of the discovery
GWAS; for details we again refer to Rautanen et al. (2015). (2) In
PROGRESS we considered two outcome measures: ﬁrst a combined bi-
nary endpoint of deathwithin 28 days or necessity of intensive care (de-
ﬁned by a ﬁrst-time requirement of ventilation, oxygenation, dialysis or
catecholamines), and second, the worst SOFA score within ﬁve days
after enrolment. Association analysis was performed using SNPTEST
version 2.5 assuming a log-additive genetic model. We adjusted for
age (linear), sex, and the ﬁrst three principal components. A total of
936 individuals had complete genetic, phenotypic and covariate data.
2.3.3. Exome Sequencing Study
We analyzed the exome sequencing data using the adjusted SKAT-O
method as implemented in the package “SKAT” (Lee et al., 2012) in R
(version 3.1.1). SKAT-O is a method to assess the cumulative effects of
all variants in a genomic region (in our case gene coding regions
±10 kb according to UCSC Genome Browser as reference (GRCh37/
hg19)). Depending on the expected power for each region, SKAT-O
runs as a “burden” or “nonburden” test. We searched for genomic asso-
ciations with the dichotomous outcome 28 day mortality adjusting for
age (linear), sex, and the ﬁrst two principal components for population
structure as covariates. In addition, we performed also sensitivity anal-
yses by including the ﬁrst ﬁve principal components and center as co-
variates. Note that the principal components were calculated within
the exome study. We limited the SKAT-O result presentation to our 21
notable genes in proximity to the best 14 discovery GWAS SNPs and
to the 14 reported genes in proximity to the best 35 GWAS SNPs from
Rautanen et al. (2015). In particular, given that SKAT-O results summa-
rize the evidence at the gene level, we decided to report all gene-level
242 A. Scherag et al. / EBioMedicine 12 (2016) 239–246statistics up- and downstream of our discovery GWAS SNPs for cases in
which the discovery GWAS SNP signal was not located within the cod-
ing region.
2.3.4. Bioinformatic Annotations and In Silico Analyses
We created regional plots of the best GWAS loci using LocusZoom
(Pruim et al., 2010). As part of the functional assessment of the detected
variants we assessed their potential deleteriousness as described in
Kircher et al. (2014). These authors developed the C-score which is
based on Combined Annotation Dependent Depletion. It estimates the
deleteriousness of a SNP or indel across a number of bioinformatic
tools (for details we refer Kircher et al., 2014)with larger values indicat-
ing higher pathogenicity potential. Next, we searched the NHGRI-EBI
GWAS catalog (https://www.ebi.ac.uk/gwas/assessed at 07/25/2016;
Welter et al., 2014) for all notable genes whereas pathways (Table 4)
were checked using http://www.genecards.org/assessed at (07/25/
2016). For loci with support from more than one data source, we ap-
plied a previously described approach (Geisel et al., 2016) using GTEx
(release version 6) and ENCODE and the UCSC Genome Browser
(GTEx Consortium, 2015; Rosenbloom et al., 2013; see Appendix) in
order to further annotated the loci.
3. Results
We identiﬁed 243 autosomal variants with suggestive evidence for
an association with 28 day mortality in the discovery GWAS of 740
European patients with treated sepsis (p b 10−5, Table 1, Fig. 1). These
variants clustered in 14 GWAS loci (Table 2) and were further validated
in two GWA studies and in an independent exome sequencing study
(Taudien et al., 2016). In addition, we identiﬁed one locus in males on
the X-chromosome (see Supplementary Fig. 15 and Supplementary
Table 3).
From the 14 lead SNPs that are markers of the 14 discovery GWAS
loci (see Fig. 2 and Appendix for regional plots), a total of 9 are located
within the coding region of genes and 8 have a minor allele frequency
(MAF) ≤5% in our patient sample. Among them is the top associated
missense variant (rs117983287; p = 8.16 × 10−8) located at chromo-
some 9q21.2 in the VPS13A (vacuolar protein sorting 13 homolog A
(S. cerevisiae)) gene (Fig. 2a, Supplementary Fig. 18). With a scaled C-
score of 22.3 this variant is predicted to be among the 1%most deleteri-
ous substitutions that one can have in thehuman genome (Kircher et al.,
2014). Our sensitivity analyses showed that the estimated odds ratios
were robust with respect to treatment groups and were sensitive to
the adjustment for the Acute Physiology and Chronic Health Evaluation
(APACHE) II score (largest change of the estimated odds ratio (33% de-
crease) of all 14 discovery GWAS signals). Furthermore, we observed an
impact of the risk variant on the 14 day average SOFA scores particularly
for the cardiovascular and the renal sub-scores (SupplementaryFig. 1.Discovery GWAS: a) Manhattan plot for the analysis of 28 daymortality in patients with
suggestive association signal (i.e. p ≤ 1 × 10−5) and the red line is the level for a genome-wide
values (λ= 1.0079) from the analysis of 28 day mortality in patients with treated sepsis (addTable 1c). While no information for this variant was available in the
meta-analysis data set by Rautanen et al. (2015) (see Table 3), the var-
iant was supported by the independent PROGRESS GWAS data (uncor-
rected p= 0.027 for the association to theworst SOFA score within ﬁve
days after enrolment; Table 3). Interestingly, the results for VPS13A in
the independent exome sequencing study also indicated evidence for
an association to 28 day mortality (pSKAT-O = 0.04; Table 4). GTEx and
ENCODE annotations are provided in Supplementary Fig. 19.
Among the GWAS loci with more frequent lead SNPs (estimated
MAF N 5%) and corresponding validation GWAS or exome sequencing
association signals, we observed p = 3.34 × 10−7 for an intergenic
SNP (rs9529561) on chromosome 13q21.33 which was also supported
by the PROGRESS data (uncorrected p = 0.035 for the association to
death within 28 days or necessity of intensive care; p = 2.4 × 10−10
in the meta-analysis). While again no data was available from the
meta-analysis by Rautanen et al. (2015), the exome data for the KLHL1
(kelch like family member 1) gene results in 375 kb distance did not
provide evidence for an association (pSKAT-O = 1.00; Table 4). For an
intronic SNP (rs2641697) of the CRISPLD2 (cysteine rich secretory pro-
tein LCCL domain containing 2) gene on chromosome 16q24.1, we ob-
served p = 5.99 × 10−6 in the discovery GWAS and pSKAT-O = 0.003
for 28 day mortality in the exome data. However, this time none of
the independent validation GWA studies supported this observation.
GTEx and ENCODE annotations for the two loci are provided in Supple-
mentary Figs. 20 and 21.
Finally, we compared the top association ﬁndings (p ≤ 10−5) from
Rautanen et al. (2015) with the results from our discovery GWAS and
exome sequencing study (Supplementary Table 2). Within the reported
12 loci with variants associated with 28 day mortality among patients
with sepsis caused by pneumonia or abdominal infections, we observed
p = 0.01 for rs2096460 located in URB1 (URB1 ribosome biogenesis 1
homolog (S. cerevisiae)) on chromosome 21q22.11 and p = 0.04 for
an intergenic variant (rs74438932) on chromosome 13 located 88 kb
downstream of GPR12 (G protein-coupled receptor 12) gene on chro-
mosome 13q12.13. However, the effect alleles in both GWAS were
directionally inconsistent and none of the available exome sequencing
association signals achieved a pSKAT-O ≤ 0.05. For details we refer to Sup-
plementary Table 2.
4. Discussion
We report results of a GWAS in patients with treated sepsis which
focused on common genetic variants associated with 28 day mortality.
We validated our best ﬁndings using three independent data sets in-
cluding two GWA and a whole-exome sequencing study. We applied
the new Sepsis-3 deﬁnition (Singer et al., 2016; Seymour et al., 2016)
in the discovery GWAS and the sequencing study which requires the
presence of organ dysfunction for a diagnosis of sepsis. Furthermore,treated sepsis (additive genetic model). The blue line represents the signiﬁcance level for a
association signal (i.e. p ≤ 5 × 10−8). b) Quantile–quantile (Q–Q) plot of all the GWAS p-
itive genetic model).
Table 2
Discovery GWAS top association signals (loci with SNP association signals that met a p-value b 10−5) for 28 day mortality among patients with treated sepsis.
SNP Chromo-some Physical
positiona
Variant type Effect
allele/other
allele
Effect allele
frequencyb
Model 1 (adjusted for
sex, age, PCc)
Model 2 (adjusted for
sex, age, PCc & APACHE II)
Notable genes
Estimated
odds ratio
p-Value Estimated
odds ratio
p-Value
rs382422 1 68,916,123 Intergenic C/G 0.22 2.1 3.21 × 10−6 2.6 8.98 × 10−7 RPE65
DEPDC1
rs58764888 3 11,217,691 Intronic A/T 0.02 13.3 6.70 × 10−7 15.0 3.60 × 10−7 HRH1
rs72862231 3 37,853,059 Intronic; NCTd A/T 0.05 4.4 1.73 × 10−6 5.0 5.12 × 10−7 ITGA9
ITGA9-AS1
rs150062338 3 188,004,948 Intronic; regulatory region T/C 0.01 38.6 2.32 × 10−7 26.1 2.03 × 10−6 LPP
rs10933728 3 194,027,568 Intronic; NCTd G/A 0.03 7.0 5.62 × 10−6 7.8 3.37 × 10−6 LINC00887
rs115550031 4 856,102 Intronic; NCTd A/G 0.02 13.8 2.45 × 10−6 17.6 7.41 × 10−7 GAK
rs62369989 5 117,409,248 Intronic; NCTd G/T 0.26 2.1 7.98 × 10−6 2.0 4.07 × 10−5 LOC102467224
rs115036193 6 33,000,554 Intronic T/C 0.01 16.2 2.21 × 10−6 11.3 2.57 × 10−5 HLA-DOA
HLA-DPA1
rs117983287 9 80,020,874 Missense A/C 0.01 18.2 8.16 × 10−8 12.1 2.18 × 10−6 VPS13A
rs150811371 12 23,661,042 Intergenic A/G 0.08 3.4 2.93 × 10−6 4.0 4.46 × 10−7 ETNK1
SOX5
rs945177 13 27,621,985 Intergenic A/G 0.02 14.7 1.31 × 10−6 12.4 5.46 × 10−6 GPR12
USP12
rs9529561 13 69,899,506 Intergenic G/A 0.08 3.9 3.34 × 10−7 3.6 1.68 × 10−8 LINC00550
KLHL1
rs2641697 16 84,885,777 Intronic; NCTd G/C 0.36 2.0 5.99 × 10−6 2.0 2.27 × 10−5 CRISPLD2
rs7211184 17 14,257,083 Intergenic; regulatory region C/G 0.72 2.0 9.43 × 10−6 2.0 5.04 × 10−6 HS3ST3B1
CDRT7
a According to GRCh37 (hg19).
b Estimated effect allele frequency in all GWAS patients.
c Principle components to address potential population stratiﬁcation effects.
d Non-coding transcript variant.
243A. Scherag et al. / EBioMedicine 12 (2016) 239–246we followed-up the best discovery loci from themost recent and largest
sepsis GWAS which applied a similar study design (Rautanen et al.,
2015).
The SNP with the strongest GWAS signal was a missense and poten-
tially deleterious variant located on chromosome9q21.2within VPS13A.
This result was supported by the validation GWAS and the exome se-
quencing data. Recent experiments (Muñoz-Braceras et al., 2015) indi-
cated an important regulatory role of VPS13A for autophagic
degradation. Autophagy is a key component of our immune system
and has also been associated to several human diseases (Cuervo andFig. 2. Regional association plot for a) the chromosome 9q21.2 locus (centered around the le
rs2641697) in the analysis of 28 day mortality in patients with treated severe sepsis/septic s
for Utah residents with northern or western European ancestry (CEU); phase 1, version 3) witMacian, 2014; Schneider and Cuervo, 2014). However, this signal is lo-
cated within a gene-rich region (9q21) that has been associated to
many complex diseases like mental disorders, type 2 diabetes mellitus,
some cancers and cardiovascular disease (An et al., 2012; Shimo et al.,
2011). Thus, VPS13Amight not be the only candidate. Notably, we also
observed a similarly strong association GWAS signal for variants in
GNA14 (guanine nucleotide binding protein (G protein), alpha 14), a
gene which is located ~200 kb distal to VPS13A. GNA14 is member of
the “G alpha Q signaling events”-pathway which is highlighted in the
accompanying report by Taudien et al. 2016. In their report, raread SNP rs117983287) and b) the chromosome 16 locus (centered around the lead SNP
hock (additive genetic model). Colors indicate the correlation (r2 in 1000 Genomes data
h the alleles of rs117983287/rs2641697.
Table 3
Validation of the autosomal SNP markers from the discovery GWAS in two independent GWA studies.
SNP Chromo-some Physical
positiona
Effect
allele/other
allele
Meta-analysis of three discovery GWAS cohorts of
Rautanen et al. (2015)
PROGRESS GWAS Meta-analysis
p-valueb
Patients with sepsis
caused by pneumonia or
abdominal infections
Patients with sepsis
caused by pneumonia
Death within 28 days or
necessity of intensive
care
Worst SOFA within
ﬁve days after
enrolment
Odds ratio for
the effect
allele
p-Value Odds ratio for
the effect
allele
p-Value Odds ratio for
the effect
allele
p-Value β for the
effect
allele
p-Value
rs382422 1 68,916,123 C/G 1.01 0.949 0.99 0.924 1.09 0.673 0.13 0.248 0.002
rs58764888 3 11,217,691 A/T 0.71 0.162 1.07 0.850 0.64 0.525 -0.44 0.224 0.090
rs72862231 3 37,853,059 A/T 1.08 0.646 1.25 0.252 0.57 0.230 0.18 0.445 0.003
rs150062338 3 188,004,948 T/C – – – – – – -0.40 0.368 –
rs10933728 3 194,027,568 G/A 0.69 0.045 0.66 0.079 0.51 0.307 0.24 0.445 0.292
rs115550031 4 856,102 A/G – – – – 0.77 0.765 0.04 0.935 2.1 × 10−5
rs62369989 5 117,409,248 G/T 0.91 0.252 0.87 0.186 1.30 0.219 0.09 0.464 0.020
rs115036193 6 33,000,554 T/C – – – – 1.15 0.821 0.22 0.554 3.1 × 10−6
rs117983287 9 80,020,874 A/C – – – – 1.47 0.569 0.95 0.027 1.1 × 10−7
rs150811371 12 23,661,042 A/G 1.03 0.803 1.03 0.871 0.83 0.547 -0.13 0.464 0.002
rs945177 13 27,621,985 A/G – – – – 1.09 0.873 0.11 0.761 2.9 × 10−6
rs9529561 13 69,899,506 G/A – – – – 1.87 0.035 -0.12 0.508 2.4 × 10−10
rs2641697 16 84,885,777 G/C 0.98 0.768 1.15 0.132 0.91 0.608 0.03 0.790 0.012
rs7211184 17 14,257,083 C/G – – – – 0.82 0.319 -0.04 0.689 3.8 × 10−4
a According to GRCh37 (hg19).
b Meta-analysis based on one-sided p-values of the discovery GWAS (model 1) and both validation GWA studies (Rautanen et al. (2015): sepsis caused by pneumonia or abdominal
infections; PROGRESS: death within 28 days or necessity of intensive care) using the weighted inverse normal (z-score) method (weighting by n; e.g. 740, 2534, 936).
244 A. Scherag et al. / EBioMedicine 12 (2016) 239–246variants in genes of the pathway, includingGNA14, were found to have a
putatively protective effect leading to a more favorable sepsis course.
Identiﬁcation of GNA14 in both studies is a strong argument that the G
alpha Q signaling pathway might play an important role in sepsis. In
contrast to our ﬁndings, Rautanen et al. (2015) did not list this 9q21
locus around VPS13A and GNA14 among their top ﬁndings. Potential ex-
planations, apart from a false positive ﬁnding in our data sets, could beTable 4
Validation of the notable genes from the discoveryGWAS in the independent exome sequencing
of the 21 notable genes no SKAT-O p-values could be calculated due to sparse data.
Chromosome Analyzed regiona Notable
genesb
Pathway(s)c
1 68,884,506–68,925,642 RPE65 (Visual) signal transduction (by G
metabolism
1 68,929,834–68,972,904 DEPDC1 No pathway known, GO-term: GO
signal transduction
3 11,284,384–11,314,939 HRH1 7 super pathways, among them G
and histamine binding
3 37,483,812–37,871,281 ITGA9 25 super pathways, among them
signal transduction by L1
3 37,785,179–37,913,271 ITGA9-AS1 –
3 187,920,720–188,618,460 LPP Stabilization and expansion of the
adherens junction
3 194,008,988–194,040,593 LINC00887 –
4 833,064–936,174 GAK Vesicle budding, membrane trafﬁ
9 79,782,360–80,007,921 VPS13A –
12 22,768,075–22,807,349 ETNK1 3 super pathways, phospholipid m
12 23,675,230–23,747,546 SOX5 4 super pathways, among them E
13 27,319,338–27,344,922 GPR12 Peptide ligand binding receptors,
A rhodopsin-like
13 27,630,286–27,756,033 USP12 Ubiquitin-proteasome dependent
13 70,264,724–70,692,625 KLHL1 –
16 84,843,586–84,953,116 CRISPLD2 –
17 14,194,505–14,259,492 HS3ST3B1 Heparan sulfate biosynthesis/met
a According to GRCh37 (hg19) ± 10 kb.
b See Table 1.
c http://www.genecards.org/.
d In the analyzed region - MAF N 0.005 as reported in at least one of three databases (ExAC no
et al. 2016).
e In the analyzed region - MAF b 0.005 or not reported in the three databases.
f Exact two-sided p-values for the SKAT-O analyses.
g G-protein coupled receptor.their exclusion of variants with minor allele frequencies b2% and/or in-
clusion of less severely affected patients by applying the 2001 sepsis
deﬁnition (Levy et al., 2003) or the general need for much larger sam-
ples size as also underlined by our power considerations.
Besides our strongest GWAS signal, we also found association signals
which have previously been associatedwith complex diseases including
sepsis phenotypes. Genomic variation in CRISPLD2 was reported to bestudy for the outcome28daymortality amongpatientswith treated sepsis. Note that for 5
# low frequency or
common variants in
survivors/non-survivorsd
# rare variants in
survivors/non-survivorse
p-Valuef
PCRg), retinol 8/7 3/1 0.12
: 0007165; 13/5 5/0 0.13
PCRg activity 3/1 1/0 0.23
GPCR g and 34/21 11/5 0.35
4/1 2/0 0.21
E-cadherin 14/13 16/9 0.48
0.84
cking 37/30 28/14 0.14
55/24 22/3 0.04
etabolism 1/1 1/1 0.27
RK signaling 6/5 3/0 0.33
GPCRsg, class 3/3 0/0 0.32
proteolysis 3/2 4/1 0.09
19/12 6/1 1.00
32/35 12/9 0.003
abolism 3/1 1/0 0.45
n-Finnish European group or ESP Americans of European ancestry or dbSNP – see Taudien
245A. Scherag et al. / EBioMedicine 12 (2016) 239–246associated with the presence of cleft lips (Mijiti et al., 2015), and recent
work showed a decreased expression of CRISPLD2 in septic shock and an
association with procalcitonin – one of the best validated biomarkers in
sepsis research (Wang et al., 2013). Furthermore, we observed some
converging support for an intergenic region on chromosome 13q21.33
whichwas previously reported to be associatedwith risk of chronic kid-
ney disease (Köttgen et al., 2010) in the GWAS catalog. However, these
authors described an intronic SNP within the DACH1 (Dachshund ho-
molog 1) gene and the SNP alleles were in linkage equilibrium. Summa-
rizing these considerations, the region on chromosome 9q21.2
including VPS13A, CRISPLD2 and to a lower extent the chromosome
13q21.33 locus are regions with a biologically plausible relationship to
sepsis which are supported by both our data sets and external evidence.
When focusing on the top association ﬁndings from Rautanen et al.
(2015), we already reported that we could not support the clinical im-
plications suggested for the FER gene (Schöneweck et al., 2015). More-
over, our data did not strongly support other candidate genes either.
However, Rautanen et al. (2015) focused on sepsis due to pneumonia
which might in part explain these discrepancies.
Our study has several strengths and limitations. Firstly, our sample
size was rather small so that the discovery GWAS was underpowered
to detect smaller genetic effects while properly controlling the (fami-
ly-wise) type I error rate. To protect against false positives, we assessed
two independent GWA validation studies and a sample of sepsis pa-
tients by exome sequencing. Here it should also be noted that none of
the markers formally replicated at a Bonferroni-corrected 0.05/
14≈ 0.003 signiﬁcance level. Secondly, the discovery GWAS patients
included were selected patients from two RCTs (Brunkhorst et al.,
2008; Brunkhorst et al., 2012) and treatment - though not affecting
the outcome differently - might have had a differential genotype-
dependent effect on 28 daymortality. To address this limitationwe con-
ducted sensitivity analyses adjusting for treatment group and obtained
fairly similar i.e. robust ﬁndings. Thirdly, a GWAS has a focus on com-
mon variation scattered across the genome while exome sequencing
detects both rare and common coding variants in the coding region.
For the given reasons one might argue that mixing both strategies is a
bad idea; others might argue that functionally relevant variation with
stronger effects might still be most likely detectable in the exome.
Fourthly, even after applying the new Sepsis-3 deﬁnition, sepsis re-
mains a highly complex phenotype. Following Rautanen et al. (2015)
more promising results might be generated by focusing on more ho-
mogenous subgroups such as sepsis patients with pneumonia. We
agree that better deﬁned subgroups (e.g. identical pathogens) might
help overcome some of the challenges faced in sepsis research (Cohen
et al., 2015). Here we applied the new Sepsis-3 deﬁnition to both the
discovery GWAS and the sequencing study and we wanted to avoid
multiplicity issues that arise if subgroups are deﬁned post-hoc (Sun
et al., 2014; Burke et al., 2015). However, the validation GWA studies
addressed a slightly different phenotype spectrum (e.g. patients with
CAP) and not exactly the same outcomes given that e.g. death is a rare
event in CAP patients. Fifthly, 28 day mortality has been criticized as
an relatively arbitrary and unspeciﬁc endpoint (Cohen et al., 2015)
and clearly genetic studies of the disease course after sepsis would be
strengthened by intermediated omic or endophenotype data (between
genomic variation and clinical outcomes). Unfortunately, such addition-
al omic data layers were not available to us in the same samples. Recent
reviews on sepsis in the ﬁeld of proteomics (Camprubí-Rimblas, 2015),
metabolomics (Fanos et al., 2014) and transcriptomics (Almansa et al.,
2015), however, did not imply any of the above mentioned genes.
Given that omic data integration in sepsis research is still in its infancy,
we think that this is an important facet of future sepsis-related genomic
research as recently demonstrated by Davenport et al. (2016).
In summary, we performed a discovery GWAS in patientswith treat-
ed sepsis which focused on common genetic variants associated with
28 day mortality and validated our best gene loci in independent
GWA studies and an exome sequencing study. GWAS and exome datasupported the VPS13A gene locus on chromosome 9q21.2. Furthermore,
we identiﬁed one region on chromosome 13q21.33 and one candidate
geneCRISPLD2which should be a focus of future omic research activities
in order to elucidate their biological inﬂuences. Future genome-wide
studies in the ﬁeld of sepsis will only be successful if more homogenous
phenotype deﬁnitions in much larger samples are applied.
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